9 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 7 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Rogaratinib: new trials by email Literature Review of Rogaratinib trials Research Report on Rogaratinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2021-05-03 | 2026-11-12 |
| Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. Combination, Rogaratinib + palbociclib + fulvestrant - Breast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of Breast | Phase 1 | Completed | Fundacion CRIS de Investigación para Vencer el Cáncer | 9 | 2020-11-25 | 2023-12-28 |
| Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression Rogaratinib - Bladder Cancer | Phase 2 | Withdrawn | Dana-Farber Cancer Institute | 2019-11-27 | 2019-12-17 | |
| Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety Rogaratinib (BAY1163877), Combination drug - Cancer | Phase 2 | Completed | Bayer | 1 | 2019-10-30 | 2022-04-01 |
| Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) Rogaratinib - Squamous-cell Non-small Cell Lung Cancer | Phase 2 | Terminated | Swiss Cancer Institute | 15 | 2019-07-25 | 2022-11-09 |
| Rogaratinib (BAY1163877) in Chinese Patients Rogaratinib (BAY1163877) - Neoplasms | Phase 1 | Completed | Bayer | 1 | 2019-01-07 | 2021-03-29 |
| Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors Rogaratinib (BAY1163877), Copanlisib (BAY80-6946) - Advanced or Metastatic Solid Tumor | Phase 1 | Completed | Bayer | 16 | 2018-07-25 | 2022-07-14 |
| Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma Rogaratinib (BAY1163877), Chemotherapy - Carcinoma, Transitional Cell | Phase 2 / Phase 3 | Completed | Bayer | 175 | 2018-05-31 | 2022-09-28 |
| Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma Rogaratinib (BAY1163877), Atezolizumab - Urothelial Carcinoma | Phase 1 | Completed | Bayer | 37 | 2018-05-15 | 2025-04-09 |
| Rogaratinib (BAY1163877) Human Mass Balance Study Rogaratinib (BAY1163877) - Clinical Trial, Phase I, Pharmacokinetics | Phase 1 | Completed | Bayer | 6 | 2018-04-06 | 2018-08-14 |
| Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors BAY1163877 - Neoplasms | Phase 1 | Completed | Bayer | 9 | 2015-12-15 | 2018-04-18 |
| Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib) Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID - Neoplasms | Phase 1 | Completed | Bayer | 168 | 2013-12-30 | 2021-05-06 |
Neoplasms (4) · Carcinoma, Transitional Cell (3) · Urinary Bladder Neoplasms (3) · Acrocephalosyndactylia (2) · Head and Neck Neoplasms (2) · Neoplasm Metastasis (2) · Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Gastrointestinal Stromal Tumors (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1)
Bayer (8) · Dana-Farber Cancer Institute (1) · Fundacion CRIS de Investigación para Vencer el Cáncer (1) · National Cancer Institute (NCI) (1) · Swiss Cancer Institute (1)
Spain (5) · United States (5) · Germany (4) · South Korea (4) · Switzerland (4) · France (3) · Japan (3) · Singapore (3) · Austria (2) · Belgium (2) · China (2) · Italy (2) · Netherlands (2) · Australia (1) · Canada (1)
Alfredo Addeo, MD (1) · Bradley A. McGregor, MD (1) · Luis Manso, MD (1) · Suzanne George (1)
PMID 30807645, PMID 31405822, PMID 36240478, PMID 38573872, PMID 39298147, PMID 42191879
2017 (2), 2016 (1), 2018 (1), 2019 (1), UM1CA186709 (1)